Nucleofection
Nucleofection is an
trademarks owned by Lonza Cologne AG, part of the Lonza Group
.
Applications
Nucleofection is a method to transfer substrates into
endogenous
gene.
Primary cells, for example
medical research
purposes. In contrast, cell lines have often been cultured for decades and may significantly differ from their origin.
Mechanism
Based on the physical method of
blood cells. Before the introduction of the Nucleofector Technology, efficient gene transfer into primary cells had been restricted to the use of viral vectors, which typically involve disadvantages such as safety risks, lack of reliability, and high cost. The non-viral gene transfer methods available were not suitable for the efficient transfection of primary cells. Non-viral delivery methods may require cell division for completion of transfection, since the DNA enters the nucleus during breakdown of the nuclear envelope upon cell division
or by a specific localization sequence.
Optimal nucleofection conditions depend upon the individual , or other biologically active molecules.
See also
References
- Kerima Maasho; Alina Marusina; Nicole M. Reynolds; John E. Coligan; Francisco Borrego (January 2004). "Efficient gene transfer into the human natural killer cell line, NKL, using the amaxa nucleofection system". Journal of Immunological Methods. 284 (1–2): 133–140. PMID 14736423.
- Pascal G. Leclere; Aliza Panjwani; Reginald Docherty; Martin Berry; John Pizzey; David A. Tonge (15 Mar 2005). "Effective gene delivery to adult neurons by a modified form of electroporation". Journal of Neuroscience Methods. 142 (1): 137–143. S2CID 38463232.
- Michela Aluigi; Miriam Fogli; Antonio Curti; Alessandro Isidori; Elisa Gruppioni; Claudia Chiodoni; Mario P. Colombo; Piera Versura; Antonia D'Errico-Grigioni; Elisa Ferri; Michele Baccarani; Roberto M. Lemoli (February 2006). "Nucleofection is an efficient non-viral transfection technique for human bone marrow-derived mesenchymal stem cells". Stem Cells. 24 (2): 454–461. PMID 16099993.